TTRX vs ARQT vs INVA vs REGN vs ABBV

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Turn Therapeutics Inc. (TTRX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus AbbVie Inc. at 87. 7x. On forward P/E, Innoviva, Inc. is actually cheaper at 7. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 0. 70x versus Regeneron Pharmaceuticals, Inc. 's 2. 47x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +107. 3%, compared to -43. 1% for Turn Therapeutics Inc. (TTRX). Over 10 years, the gap is even starker: ABBV returned +311. 6% versus TTRX's -43. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 11β versus Arcutis Biotherapeutics, Inc. 's 1. 50β — meaning ARQT is approximately 1217% more volatile than INVA relative to the S&P 500. On balance sheet safety, Turn Therapeutics Inc. (TTRX) carries a lower debt/equity ratio of 2% versus 23% for Innoviva, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -76. 9% for Turn Therapeutics Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 0. 70x versus Regeneron Pharmaceuticals, Inc. 's 2. 47x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Innoviva, Inc. (INVA) trades at 7. 3x forward P/E versus 104. 1x for Arcutis Biotherapeutics, Inc. — 96. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INVA: 75. 9% to $40. 00.

In this comparison, ABBV (3.

2% yield), REGN (0. 5% yield) pay a dividend. TTRX, ARQT, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 2% yield, +311. 6% 10Y return). Both have compounded well over 10 years (ABBV: +311. 6%, ARQT: -5. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TTRX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; INVA is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while TTRX, ARQT, INVA, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.